Compare Amphastar Pharmaceuticals Inc (AMPH) vs Roundhill Innov-100 0DTE Covered Call Strat ETF (QDTE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Roundhill Innov-100 0DTE Covered Call Strat ETF — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $30.24. The key difference: Roundhill Innov-100 0DTE Covered Call Strat ETF is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | QDTE | |
|---|---|---|
Market Cap | $826.08M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $30.81 | $36.60 |
52-Week Low | $16.87 | $26.85 |
Enterprise Value | $1.22B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
QDTE trades at $30.495, up 0.35% on the day, with a bearish technical outlook from moving averages and a neutral signal from oscillators. The ETF focuses on weekly dividend distributions from a 0DTE covered call strategy on a synthetic Nasdaq portfolio, attracting income investors. Recent news highlights its high distribution yield, though volatility has declined.
The outlook remains cautious due to technical bearishness and reliance on options income, which is sensitive to market volatility. Risks include yield compression from lower volatility and competitive pressure from similar ETFs. Analyst sentiment is mixed, emphasizing yield attractiveness but noting total return underperformance versus benchmarks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Roundhill Innov-100 0DTE Covered Call Strat ETF
QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on QDTE →
